RecruitingPhase 1Phase 2NCT05853601

Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage


Sponsor

Medical College of Wisconsin

Enrollment

30 participants

Start Date

Oct 17, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Acute kidney injury is a significant complication for infants who experience hypoxic ischemic encephalopathy, being associated with increased rates of death and prolonged hospitalization. This pilot study of theophylline administration soon after birth for the prevention of kidney injury will lay the foundation for the conduct of a larger clinical trial that seeks to identify a theophylline as a novel therapy to prevent kidney injury in thousands of at-risk infants.


Eligibility

Min Age: 1 HourMax Age: 18 Hours

Inclusion Criteria5

  • gestational age at birth >= 35 weeks by best obstetrical dating
  • birth weight > 1800 grams
  • clinical determination of HIE and treatment with hypothermia being initiated within six hours of birth according to institutional guidelines
  • no known congenital abnormalities involving the brain, kidneys, heart or lungs
  • ability to administer theophylline via intravenous route within 18 hours of birth

Exclusion Criteria6

  • infants with suspected or diagnosed significant renal, urinary tract, brain, heart, or lung abnormalities
  • infant with known chromosomal anomaly
  • evidence of head trauma or skull fracture causing major intracranial hemorrhage
  • inability to initiate hypothermia within six hours of birth
  • attending physician unwilling to have infant participate in the study
  • inability to obtain informed consent within 18 hours of birth

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSingle Dose Theophylline

Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 18 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.

DRUGRepeat Dose Theophylline

Subjects are given a loading dose of theophylline, 5mg/kg IV, within 18 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.


Locations(1)

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05853601


Related Trials